Condition
Heart Failure
Systemic Inflammation
Locations
Argentina, Australia, Bulgaria, Canada, Czechia, France, Germany,
Greece, India, Malaysia, Poland, Spain, Turkey, United Kingdom, United States
Start date
01/04/2024
Identifiers
Trial ID
NN6018-4914,
NCT number NCT06200207,
Eudract number Not Available
NCT number NCT06200207,
Eudract number Not Available
Summary
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Trial Overview:
Treatment
DRUG: Ziltivekimab
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Apr 01 2024 - Jan 12 2027
Participants
680
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.